| Literature DB >> 32571447 |
Michael S Calderwood1, Valerie M Deloney2, Deverick J Anderson3, Vincent Chi-Chung Cheng4,5, Shruti Gohil6, Jennie H Kwon7, Lona Mody8, Elizabeth Monsees9, Valerie M Vaughn8, Timothy L Wiemken10, Matthew J Ziegler11, Eric Lofgren12.
Abstract
To understand hospital policies and practices as the COVID-19 pandemic accelerated, the Society for Healthcare Epidemiology of America (SHEA) conducted a survey through the SHEA Research Network (SRN). The survey assessed policies and practices around the optimization of personal protection equipment (PPE), testing, healthcare personnel policies, visitors of COVID-19 patients in relation to procedures, and types of patients. Overall, 69 individual healthcare facilities responded in the United States and internationally, for a 73% response rate.Entities:
Mesh:
Year: 2020 PMID: 32571447 PMCID: PMC7360941 DOI: 10.1017/ice.2020.303
Source DB: PubMed Journal: Infect Control Hosp Epidemiol ISSN: 0899-823X Impact factor: 3.254
SHEA Research Network (SRN) Facilities by Bed Size
| Hospital Size, No. of Beds | No. (n=57)[ | % |
|---|---|---|
| 1–200 | 9 | 15.8 |
| 201–400 | 11 | 19.3 |
| 401–600 | 10 | 17.5 |
| 601–800 | 8 | 14.0 |
| 801–1,000 | 11 | 19.3 |
| >1,000 | 7 | 12.3 |
1 unspecified.
Personal Protection Equipment (PPE) Optimization Strategies (n = 69)
| Characteristic | Certain Units, No. (%) | All Clinical Care Areas (Including Ambulatory Areas), No. (%) | Entire Facility, No. (%) | Total Facilities, No. (%) |
|---|---|---|---|---|
| Universal HCP respirator use | 41 (59.4) | 0 | 0 | 41 (59.4) |
| Universal HCP surgical masking | 5 (7.2) | 28 (40.6) | 36 (52.2) | 63 (91.3) |
|
| ||||
| Respirator extended use, 1 d | 26 (37.7) | 6 (8.7) | 5 (7.2) | 36 (52.2) |
| Respirator extended use, >1 d | 12 (17.4) | 9 (13.0) | 6 (8.7) | 25 (36.2) |
| Respirator extended use with surgical mask or cloth mask | 12 (17.4) | 5 (7.2) | 3 (4.3) | 17 (24.6) |
| Gown extended use | 7 (10.1) | 6 (8.7) | 6 (8.7) | 19 (27.5) |
|
| ||||
| Respirator reprocessing by vaporized hydrogen peroxide | 11 (15.9) | 7 (10.1) | 8 (11.6) | 23 (33.3) |
| Respirator reprocessing by ultraviolet irradiation | 6 (8.7) | 4 (5.8) | 3 (4.3) | 11 (15.9) |
| Respiratory reprocessing by ethylene oxide | 1 (1.4) | 1 (1.4) | 1 (1.4) | 3 (4.3) |
Note. HCP, healthcare personnel.
Use of N95 or Equivalent Respirator by Procedure Type
| Procedure | Suspected or Confirmed COVID-19 (n = 69), No. (%) | COVID-19 Not Suspected (n = 36), No. (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| N95 or Equivalent | Surgical Mask | Eyewear | Respirator Allowed but Not Recommended | N95 or Equivalent | Surgical Mask | Eyewear | Respirator Allowed but Not Recommended | |
|
| ||||||||
| In-room | 44 (63.8) | 25 (36.2) | 57 (82.6) | 6 (8.7) | 11 (30.6) | 11 (30.6) | 15 (41.7) | 3 (8.3) |
| Outdoor | 40 (58.0) | 25 (36.0) | 55 (79.7) | 5 (7.2) | 11 (30.6) | 10 (27.8) | 15 (41.7) | 2 (5.6) |
|
| ||||||||
| Intubation | 66 (95.6) | 1 (1.4) | 49 (71.0) | 1 (1.4) | 26 (72.2) | 5 (13.9) | 18 (50.0) | 4 (11.1) |
| Bronchoscopy | 66 (95.6) | 2 (2.9) | 48 (69.6) | 0 | 25 (69.4) | 3 (8.3) | 17 (47.2) | 4 (11.1) |
| Extubation | 65 (94.2) | 2 (2.9) | 49 (71.0) | 1 (1.4) | 24 (66.7) | 6 (16.7) | 17 (47.2) | 5 (13.9) |
| ENT surgery | 63 (91.3) | 4 (5.8) | 48 (69.6) | 1 (1.4) | 22 (61.1) | 5 (13.9) | 16 (44.4) | 3 (8.3) |
| Bag masking | 62 (89.9) | 4 (5.8) | 49 (71.0) | 1 (1.4) | 20 (55.6) | 8 (22.2) | 16 (44.4) | 4 (11.1) |
| ENT scope | 62 (89.9) | 1 (1.4) | 48 (69.6) | 0 | 20 (55.6) | 6 (16.7) | 16 (44.4) | 3 (8.3) |
| HFOV | 59 (85.5) | 3 (4.3) | 45 (65.2) | 1 (1.4) | 14 (38.9) | 8 (22.2) | 12 (33.3) | 2 (5.6) |
| Induction of sputum | 59 (85.5) | 4 (5.8) | 48 (69.6) | 1 (1.4) | 18 (50.0) | 7 (10.1) | 15 (41.7) | 2 (5.6) |
| Medication via nebulizer | 58 (84.1) | 3 (4.3) | 47 (68.1) | 1 (1.4) | 13 (36.1) | 9 (13.0) | 12 (33.3) | 2 (5.6) |
| Noninvasive ventilation | 57 (82.6) | 7 (10.1) | 46 (66.7) | 1 (1.4) | 13 (36.1) | 10 (14.5) | 13 (36.1) | 2 (5.6) |
| HFNO with humidification | 56 (81.2) | 7 (10.1) | 46 (66.7) | 1 (1.4) | 11 (30.6) | 9 (13.0) | 12 (33.3) | 2 (5.6) |
| When ventilator circuits are broken | 54 (78.3) | 8 (11.6) | 47 (68.1) | 1 (1.4) | 12 (33.3) | 10 (14.5) | 14 (38.9) | 2 (5.6) |
| Chest compressions | 54 (78.3) | 7 (10.1) | 46 (66.7) | 1 (1.4) | 11 (30.6) | 13 (18.8) | 16 (44.4) | 3 (8.3) |
| Use of secretion-clearing devices | 54 (78.3) | 8 (11.6) | 47 (68.1) | 2 (2.9) | 12 (33.3) | 12 (17.4) | 15 (41.7) | 2 (5.6) |
| HFNO without humidification | 53 (76.8) | 7 (10.1) | 47 (68.1) | 1 (1.4) | 11 (30.6) | 9 (13.0) | 11 (30.6) | 2 (5.6) |
| Video-assisted thorascopic surgery | 51 (73.9) | 10 (14.5) | 43 (62.3) | 0 | 13 (36.1) | 9 (13.0) | 13 (36.1) | 2 (5.6) |
| Presence of tracheostomy | 46 (66.7) | 13 (18.8) | 50 (72.5) | 4 (5.8) | 10 (27.8) | 13 (18.8) | 14 (38.9) | 1 (2.8) |
| Chest tube placement | 37 (53.6) | 22 (31.9) | 46 (66.7) | 4 (5.8) | 8 (22.2) | 13 (18.8) | 12 (33.3) | 2 (5.6) |
|
| ||||||||
| Caesarean section | 35 (50.7) | 19 (27.5) | 46 (66.7) | 3 (4.3) | 8 (22.2) | 14 (38.9) | 15 (41.7) | 4 (11.1) |
| 2nd stage of labor | 32 (46.4) | 19 (27.5) | 45 (65.2) | 2 (2.9) | 8 (22.2) | 13 (36.1) | 15 (41.7) | 4 (11.1) |
| Nonsurgical delivery | 30 (43.5) | 23 (33.3) | 45 (65.2) | 2 (2.9) | 6 (16.7) | 15 (41.7) | 15 (41.7) | 5 (13.9) |
| Care of preterm babies in isolates with NIV | 39 (56.5) | 15 (21.7) | 45 (65.2) | 1 (1.4) | 8 (22.2) | 13 (36.1) | 12 (33.3) | 3 (8.3) |
|
| ||||||||
| CABG with internal mammary artery | 28 (40.6) | 19 (27.5) | 39 (56.5) | 4 (5.8) | 5 (13.9) | 14 (38.9) | 13 (36.1) | 3 (8.3) |
| CABG with redo sternotomy | 28 (40.6) | 20 (29.0) | 40 (58.0) | 4 (5.8) | 5 (13.9) | 15 (41.7) | 13 (36.1) | 3 (8.3) |
|
| ||||||||
| Electrocautery of blood | 27 (39.1) | 23 (33.3) | 46 (66.7) | 5 (7.2) | 2 (5.6) | 17 (47.2) | 12 (33.3) | 3 (8.3) |
| Electrocautery of GI tissue | 30 (43.5) | 22 (31.9) | 47 (68.1) | 5 (7.2) | 3 (8.3) | 17 (47.2) | 13 (36.1) | 3 (8.3) |
| Electrocautery of other body fluids | 27 (39.1) | 25 (36.2) | 46 (66.7) | 5 (7.2) | 2 (5.6) | 18 (50.0) | 13 (36.1) | 4 (11.1) |
|
| ||||||||
| Endoscopy | 46 (66.7) | 15 (21.7) | 45 (65.2) | 4 (5.8) | 13 (36.1) | 12 (33.3) | 16 (44.4) | 5 (13.9) |
| Laparoscopy | 32 (46.4) | 25 (36.2) | 46 (66.7) | 3 (4.3) | 7 (19.4) | 16 (44.4) | 14 (38.9) | 5 (13.9) |
| Neurosurgery | 34 (49.3) | 26 (37.7) | 47 (68.1) | 4 (5.8) | 5 (13.9) | 16 (44.4) | 14 (38.9) | 5 (13.9) |
Note. ENT, ear, nose, throat; HFOV, High-frequency oscillating ventilation; HFNO, High-flow nasal oxygen; CABG, coronary artery bypass grafting; NIV, noninvasive ventilation; GI, gastrointestinal.
Preprocedural Testing on Asymptomatic Patients (n = 42)
| Procedure Type | Facilities Testing, No. (%) | Specific Examples Provided by Respondents |
|---|---|---|
| All procedures | 9 (21.4) | With exception of radiology for one response |
| Upper airway | 9 (21.4) | ENT, tracheostomy, bronchoscopy, intubation |
| Labor and delivery | 6 (14.3) | Including vaginal, Cesarean section, scheduled |
| Endoscopy | 5 (11.9) | Upper endoscopy, colonoscopy, ERCP, EUS, laparoscopy, peritoneal insufflation, GI endoscopy |
| Lower airway | 5 (11.9) | Intrathoracic, interventional pulmonary, bronchoscopy, pulmonary |
| Aerosol-generating procedures | 4 (9.5) | Specifically written by respondent as “aerosol-generating procedure” by respondent |
| Sedation | 4 (9.5) | General endotracheal anesthesia |
| Multiple procedures (unspecified) | 4 (9.5) | |
| All admissions | 3 (7.1) | |
| Cardiac | 3 (7.1) | Electrophysiology, cardiac catheter lab, pacemaker, transesophageal echo test |
| Chemotherapy | 3 (7.1) | Lymphodepleting therapy |
| Dental/facial | 2 (4.8) | Oral and maxillofacial surgery |
| Elective surgery | 2 (4.8) | Including if surgery could be postponed or clinical treatment altered based on positive test |
| Gastrointestinal | 2 (4.8) | Intra-abdominal |
| Transplant | 2 (4.8) | Allograft, pretransplant, autologous stem cell transplant |
| Emergency surgery | 1 (2.4) | Within 48 h |
| Neurologic | 1 (2.4) | Electroconvulsive therapy |
Note. ENT, ear, nose, and throat; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound.
Visitors of Patients Suspected or Confirmed for COVID-19
| Characteristic | Facilities, No./Total (%) | Visitors, No. (No./Total, %) | PPE Required, No./Total (%) |
|---|---|---|---|
| Visitors not allowed for COVID-19 patients | 15/64 (23.4) | N/A | N/A |
| Some or all visitors allowed | 49/64 (76.6) | N/A | N/A |
| Visitors allowed for all COVID-19 patients | 5/64 (7.8) | N/A | N/A |
| End of life | 45/64 (70.3) | 1 (31/45, 68.9) | 41/45 (91.1) |
| Birthing partners[ | 37/63 (58.7) | 1 (36/37, 97.3) | 28/37 (75.7) |
| Pediatric patients[ | 40/63 (63.4) | 1 (34/40, 85) | 31/40 (77.5) |
One facility opted out of the question regarding birthing partners and pediatric patients.